Tilogotamab Biosimilar Monoclonal Antibody (DR5) for Research

Cat No.: GMP-Bios-ab-574

Pre-Made Tilogotamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.



Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-574-1mg 1mg 3090

Size： 1mg | 10mg | 100mg



Product Details

Products Name (INN Index) Pre-Made Tilogotamab biosimilar, Whole mAb, Anti-TNFRSF10B/TRAIL-R2 Antibody: Anti-DR5/CD262/KILLER/TRICK2/TRICKB/ZTNFR9/TRAILR2/TRICK2A/TRICK2B/KILLER/DR5 therapeutic antibody
INN Name Tilogotamab
TargetTRAIL-R2
FormatWhole mAb
Derivation
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-I/II
Est. StatusActive
100% SI StructureNone
99% SI Structure6t3j:CD:HI
95-98% SI StructureNone
Year Proposed2019
Year Recommended2020
CompaniesGenmab
Conditions Approvedna
Conditions ActiveSolid tumours
Conditions Discontinuedna
Development Techna



About target - TNFRSF10B

1. Protein Tumor necrosis factor receptor superfamily member 10B

2. Gene TNFRSF10B

3. Organism Homo sapiens (Human)

Function
Receptor for the cytotoxic ligand TNFSF10/TRAIL (PubMed:10549288).
The adapter molecule FADD recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. Promotes the activation of NF-kappa-B. Essential for ER stress-induced apoptosis.